EANS-News: Epigenomics AG to Update on Clinical Studies with Septin9 Blood Test for Colorectal Cancer at Two Conferences in Europe and the US

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information/Molecular diagnostics

BERLIN and SEATTLE - October 22, 2010 (euro adhoc) - Epigenomics AG,
the cancer diagnostics company, today announced that it will present
data from two clinical studies with its proprietary biomarker for the
blood-based detection of colorectal cancer at two conferences in
Europe and the US during the next week.

The two poster presentations will include data form the recently
successfully completed prospective PRESEPT Study as well as a
follow-up study performed to independently validate the diagnostic
assay that had been used in the PRESEPT Study.

On Tuesday, October 26, 2010, Dr. Juergen Beck, M.D., Senior Vice
President Medical Affairs at Epigenomics, will present clinical data
at the 18th United European Gastroenterology Week (UEGW) in
Barcelona, Spain.

Joseph Romagnuolo M.D., Associate Professor of Medicine in the
Division of Gastroenterology and Hepatology at the Medical University
of South Carolina will present study data at the American Association
for Cancer Research (AACR) Special Conference "Colorectal Cancer:
Biology to Therapy" in Philadelphia, PA, USA on Friday, October 29,
2010.

Prof. Romagnuolo participated as a Clinical Investigator in the
PRESEPT Study.

Conference Presentation Details

18th United European Gastroenterology Week (UEGW)
October 23-28, 2010
Centre Convencions Internacional Barcelona CCIB, Barcelona, Spain
Poster Presentation: Poster P0990
October 26, 2010, 9 am - 5 pm

AACR Special Conference "Colorectal Cancer: Biology to Therapy"
October 27- 30, 2010
Loews Philadelphia Hotel, Philadelphia, Pennsylvania, USA
Poster Presentation: Poster Session B, Board B29
October 29, 2010, 5 pm - 7 pm

- Ends-

Contact Epigenomics AG:

Dr. Achim Plum

Sen. VP Corporate Development
Epigenomics AG
Tel +49 (0) 30 24345 368
pr@epigenomics.com
www.epigenomics.com

Notes to Editors

About Epigenomics

Epigenomics AG is a molecular diagnostics company with a focus on the
development of novel products for cancer. Using DNA methylation
biomarkers, Epigenomics´ tests on the market and in development for
colorectal, lung, and prostate cancer aim at aiding in an earlier and
more accurate diagnosis of these diseases thereby potentially
increasing the patient´s chances of survival.

For development and global commercialization of IVD test products,
Epigenomics pursues a dual business strategy in which direct
commercialization of proprietary diagnostic test products is combined
with non-exclusive licensing to diagnostic industry players with
broad customer access. Strategic diagnostics industry partners
include Abbott Molecular, Sysmex Corporation, Quest Diagnostics
Incorporated, and ARUP Laboratories, Inc. for diagnostics test
products and services, and QIAGEN N.V. for sample preparation
solutions and research products.

The company is headquartered in Berlin, Germany, and has a wholly
owned subsidiary, Epigenomics Inc., in Seattle, WA, USA. For more
information, please visit Epigenomics´ website at
www.epigenomics.com.

Epigenomics´ legal disclaimers. This communication expressly or
implicitly contains certain forward-looking statements concerning
Epigenomics AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward- looking statements contained herein as a result of new
information, future events or otherwise.

The information contained in this communication does not constitute
nor imply an offer to sell or transfer any product, and no product
based on this technology is currently available for sale by
Epigenomics in the United States of America. The analytical and
clinical performance characteristics of any product based on this
technology which may be sold at some future time in the USA have not
been established.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Epigenomics AG

Dr. Achim Plum

Sen. VP Corporate Development

Tel: +49 30 24345 368

achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade